Onkologie. 2010:4(4):247-250

Immune profile of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors - literary review

Peter Rohoň1,2, Kimmo Porkka2, Satu Mustjoki2
1 Hemato-onkologická klinika FN a LF UP v Olomouci
2 Hematology Research Unit, Biomedicum Helsinki, Fínsko

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cell with myeloid differentiation predominantly.

Tyrosine kinase inhibitors (TKI) (imatinib, dasatinib, nilotinib) are the current standard treatment in CML. In addition to the BCR-ABL oncoprotein,

they also inhibit off-target kinases (e. g. c-KIT, SRC, TEC). Some of these kinases have physiological functions in immune responses. In

vitro studies have implied immunosuppressive effects of TKI, but comprehensive data form in vivo analyses has been missing. In summary,

in a distinct subgroup of dasatinib-treated patients, immune reactivity is significantly enhanced warranting careful follow-up.

Keywords: chronic myeloid leukemia, tyrosine kinase inhibitors, immunomodulation

Published: October 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rohoň P, Porkka K, Mustjoki S. Immune profile of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors - literary review. Onkologie. 2010;4(4):247-250.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia. Best Practice & Research Clinical Haematology 2009; 22: 295-302. Go to original source... Go to PubMed...
    2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356. Go to original source...
    3. Indrák K, Faber E, Jarošová M. Léčba chronické myeloidní leukemie (CML) v éřě imatinibu. Vnitř. Lék. 2009; 55: 65-73.
    4. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves eficacy and improves tolerability in imatinib-resistant and imatinib-intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204-3212. Go to original source... Go to PubMed...
    5. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN 107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 2005; 7: 129-132. Go to original source... Go to PubMed...
    6. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60. Go to original source... Go to PubMed...
    7. Mustjoki S, Rohon P, Rapakko K, et al. Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph (+) CD34+ CD38neg) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy. Leukemia 2010; 24: 219-222. Go to original source... Go to PubMed...
    8. Reuben JM, Lee BN, Johnson H, et al. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Clin Cancer Res 2000; 6: 1671-1677.
    9. Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14: 2484-2491. Go to original source... Go to PubMed...
    10. Dietz AB, Souan L, Knutson GJ, et al. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094-1099. Go to original source... Go to PubMed...
    11. Blake S, Bruce Lyons A, Fraser CK, et al. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111: 4415-4416. Go to original source... Go to PubMed...
    12. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398-1405. Go to original source... Go to PubMed...
    13. Sillaber C, Herrmann H, Bennett K, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. European journal of clinical investigation 2009; 39: 1098-1109. Go to original source... Go to PubMed...
    14. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 23: 2408-2417. Go to original source... Go to PubMed...
    15. Kreutzman A, Juvonen V, Karisto V, et al. Mono/oligoclonal T- and NK-cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010; DOI 10.1182/blood-2009-12-256800. Go to original source... Go to PubMed...
    16. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. The Lancet 2005; 365: 631-632. Go to original source... Go to PubMed...
    17. Rezvani K, Grube M, Brenchley J, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102: 2892-2900. Go to original source... Go to PubMed...
    18. Rohon P, Mustjoki S, Porkka K. Differential Effects of Imatinib and Dasatinib On Immune Effector Cells in Patients with Chronic Myeloid Leukemia (CML). ASH 2009, abstract 3285. Go to original source...
    19. Mustjoki S, Lundan T, Knuutila S, et al. Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia. Leukemia 2007; 11: 2363-2368. Go to original source... Go to PubMed...
    20. Ke X, Wang J, Li L, et al. Roles of CD4+CD25 (high) FOXP3+ Tregs in lymphomas and tumors are complex. Front Biosci 2008; 13: 3986-4001. Go to original source...
    21. Steegmann JL, Moreno G, Alaez C, et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003; 7: 762-768.
    22. Rohon P, Porkka K, Mustjoki S. Effect of tyrosine kinase inhibitors on regulatory T-cells (Tregs) in patients with chronic myeloid leukemia (CML). Haematologica 2008; 93(s1): 44.
    23. Usuki K, Yokoyama K, Nagamura-Inoue T, et al. CD8+ memory T cells predominate over naive T cells in therapy-free CML patients with sustained major molecular response. Leuk Res 2009; 9: 164-165. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.